James Wymer, MD, FAAN
Professor & Division Chief; Melvin Greer Professor
Department:
MD-NEUROMUSCULAR NEUROLOGY
Business Phone:
(352) 273-5550
Business Email:
james.wymer@neurology.ufl.edu
About James Wymer
My name is Dr. James Wymer, I’m a neurologist and professor practicing at the University of Florida. I specialize in diagnosis and management of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, muscle diseases, and peripheral neuropathies. I have extensive experience in clinical research, having been a principal investigator on numerous clinical trials, including studies of ALS, diabetic neuropathy, multiple sclerosis, migraine headaches, and epilepsy. I am a fellow of the American Academy of Neurology (AAN) and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), as well as a member of several national consortiums to research neuropathic pain and ALS.
My clinical interests include: • ALS or Lou Gehrig’s Disease • Neuromuscular diseases • Hereditary Neuropathy • Muscle disease • Multiple Sclerosis • Diabetic neuropathy • Migraine headaches • Neurofibromatosis
Teaching Profile
Courses Taught
2021
PAS5020 Intro to Medicine 2
2021
MDC7800 Neurology Clerkship
Board Certifications
-
NeurologyAmerican Board of Psychiatry and Neurology
Clinical Profile
Dr. James Wymer is a neurologist and professor practicing at The University of Florida in Gainesville, Florida. He specializes in the diagnosis and management of neuromuscular diseases including amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, muscles diseases and peripheral neuropathies. Dr. Wymer has an extensive experience in clinical research, and has been the principal investigator in numerous clinical trials including studies of ALS, diabetic neuropathy, multiple sclerosis, migraine headaches and epilepsy. He is a fellow of the American Academy of Neurology (AAN) and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). He is a member of several national consortiums to research neuropathic pain and ALS.
Specialties
- Neurology
Subspecialties
- Neuromuscular Medicine
Areas of Interest
- Amyotrophic lateral sclerosis (ALS)
- Migraine
- Multiple sclerosis
- Neurofibromatosis 2
- Neurofibromatosis-1
- Neuromuscular disorders
- Peripheral Neuropathy
Research Profile
Areas of Interest
- ALS
- Muscular dystrophy
- Neuropathy
Publications
Academic Articles
2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
JAMA network open.
8(2)
[DOI] 10.1001/jamanetworkopen.2024.59058.
[PMID] 39960672.
2024
Diagnoses of muscular dystrophy in a veterans health system.
Muscle & nerve.
70(2):273-278
[DOI] 10.1002/mus.28112.
[PMID] 38783566.
2024
Leveraging deep single-soma RNA sequencing to explore the neural basis of human somatosensation.
Nature neuroscience.
27(12):2326-2340
[DOI] 10.1038/s41593-024-01794-1.
[PMID] 39496796.
2024
Relationship between pulmonary, cough, and swallowing functions in individuals with amyotrophic lateral sclerosis.
Muscle & nerve.
70(1):140-147
[DOI] 10.1002/mus.28113.
[PMID] 38742544.
2023
Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
Annals of clinical and translational neurology.
10(8):1296-1304
[DOI] 10.1002/acn3.51821.
[PMID] 37265174.
2023
Functional Lingual Pressure Thresholds for Swallowing Safety and Efficiency Impairments in Amyotrophic Lateral Sclerosis.
Dysphagia.
38(2):676-685
[DOI] 10.1007/s00455-022-10499-1.
[PMID] 35907088.
2023
Maximum lingual pressure impacts both swallowing safety and efficiency in individuals with amyotrophic lateral sclerosis.
Neurogastroenterology and motility.
35(4)
[DOI] 10.1111/nmo.14521.
[PMID] 36573040.
2023
Maximum Phonation Time as a Surrogate Marker for Airway Clearance Physiologic Capacity and Pulmonary Function in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR.
66(4):1165-1172
[DOI] 10.1044/2022_JSLHR-22-00522.
[PMID] 36877985.
2023
Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
Expert review of neurotherapeutics.
23(10):859-866
[DOI] 10.1080/14737175.2023.2251687.
[PMID] 37646130.
2023
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film.
Clinical pharmacology in drug development.
12(1):57-64
[DOI] 10.1002/cpdd.1168.
[PMID] 36168148.
2023
Predictors of Peak Expiratory Cough Flow in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia.
38(2):719-725
[DOI] 10.1007/s00455-022-10503-8.
[PMID] 35931882.
2023
Primary lateral sclerosis natural history study – planning, designing, and early enrollment.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
24(5-6):394-404
[DOI] 10.1080/21678421.2022.2161912.
[PMID] 36576200.
2023
Profiles of Dysarthria and Dysphagia in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR.
66(1):154-162
[DOI] 10.1044/2022_JSLHR-22-00312.
[PMID] 36525626.
2023
Profiling Number of Swallows per Bolus and Residue in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR.
66(10):3763-3772
[DOI] 10.1044/2023_JSLHR-23-00209.
[PMID] 37591233.
2023
Respiratory Strength Training in Amyotrophic Lateral Sclerosis: A Double-Blind, Randomized, Multicenter, Sham-Controlled Trial.
Neurology.
100(15):e1634-e1642
[DOI] 10.1212/WNL.0000000000206830.
[PMID] 36805435.
2023
Respiratory therapies for Amyotrophic Lateral Sclerosis: A state of the art review.
Chronic respiratory disease.
20
[DOI] 10.1177/14799731231175915.
[PMID] 37219417.
2023
Sensitivity and specificity of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised to detect dysarthria in individuals with amyotrophic lateral sclerosis.
Muscle & nerve.
68(3):296-302
[DOI] 10.1002/mus.27923.
[PMID] 37345346.
2023
Temporal serum metabolomic and lipidomic analyses distinguish patients with access-related hand disability following arteriovenous fistula creation.
Scientific reports.
13(1)
[DOI] 10.1038/s41598-023-43664-z.
[PMID] 37798334.
2023
The natural history of ALS: Baseline characteristics from a multicenter clinical cohort.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
1-9
[DOI] 10.1080/21678421.2023.2232812.
[PMID] 37461167.
2022
Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: A preliminary study.
Experimental neurology.
347
[DOI] 10.1016/j.expneurol.2021.113890.
[PMID] 34624328.
2022
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
Molecular Neurodegeneration.
17(1)
[DOI] 10.1186/s13024-022-00515-1.
[PMID] 35073950.
2022
Discriminant ability of the 3-ounce water swallow test to detect aspiration in amyotrophic lateral sclerosis.
Neurogastroenterology and motility.
34(7)
[DOI] 10.1111/nmo.14310.
[PMID] 34936158.
2022
Discriminant Ability of the Eating Assessment Tool-10 to Detect Swallowing Safety and Efficiency Impairments.
The Laryngoscope.
132(12):2319-2326
[DOI] 10.1002/lary.30043.
[PMID] 35137963.
2022
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
Journal of neurology, neurosurgery, and psychiatry.
93(8):871-5
[DOI] 10.1136/jnnp-2022-329024.
[PMID] 35577511.
2022
Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia.
37(3):644-654
[DOI] 10.1007/s00455-021-10315-2.
[PMID] 34037850.
2021
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
22(3-4):287-299
[DOI] 10.1080/21678421.2020.1822410.
[PMID] 32969758.
2021
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Muscle & nerve.
63(1):31-39
[DOI] 10.1002/mus.27091.
[PMID] 33063909.
2021
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
JAMA neurology.
78(1):68-76
[DOI] 10.1001/jamaneurol.2020.2590.
[PMID] 32809014.
2021
Reflexive Airway Sensorimotor Responses in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia.
36(4):574-582
[DOI] 10.1007/s00455-020-10171-6.
[PMID] 32778945.
2020
Clinical care and therapeutic trials in PLS.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
21(sup1):67-73
[DOI] 10.1080/21678421.2020.1837180.
[PMID] 33602017.
2020
Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis.
PloS one.
15(8)
[DOI] 10.1371/journal.pone.0236804.
[PMID] 32790801.
2020
Management of Primary Lateral Sclerosis
Current Treatment Options in Neurology.
22(10)
[DOI] 10.1007/s11940-020-00640-6.
2020
Preface: promoting research in PLS: current knowledge and future challenges.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
21(sup1):1-2
[DOI] 10.1080/21678421.2020.1840795.
[PMID] 33602018.
2020
Sleep disorders in myotonic dystrophies.
Muscle & nerve.
62(3):309-320
[DOI] 10.1002/mus.26866.
[PMID] 32212331.
2020
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
The New England journal of medicine.
383(10):919-930
[DOI] 10.1056/NEJMoa1916945.
[PMID] 32877582.
2019
Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis.
Muscle & nerve.
59(5):531-536
[DOI] 10.1002/mus.26408.
[PMID] 30620104.
2018
Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
19(3-4):311-312
[DOI] 10.1080/21678421.2017.1404109.
[PMID] 29205054.
2018
Combined respiratory training in an individual with C9orf72 amyotrophic lateral sclerosis.
Annals of clinical and translational neurology.
5(9):1134-1138
[DOI] 10.1002/acn3.623.
[PMID] 30250869.
2018
Targeting the Neuromuscular Junction in ALS.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
15(3):713-714
[DOI] 10.1007/s13311-018-0647-y.
[PMID] 30006767.
2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
14(3):762-772
[DOI] 10.1007/s13311-016-0508-5.
[PMID] 28070747.
2017
Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
14(3)
[DOI] 10.1007/s13311-017-0517-z.
[PMID] 28283968.
2017
Increasing Evidence for an Association Between Amyotrophic Lateral Sclerosis and Psychiatric Disorders.
JAMA neurology.
74(12):1396-1398
[DOI] 10.1001/jamaneurol.2017.1920.
[PMID] 29049449.
2017
Paraneoplastic Lambert-Eaton Myasthenic Syndrome With Limbic Encephalitis: Clinical Correlation With the Coexistence of Anti-VGCC and Anti-GABAB Receptor Antibodies.
Journal of clinical neuromuscular disease.
19(2):84-88
[DOI] 10.1097/CND.0000000000000192.
[PMID] 29189554.
2017
The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States.
Amyotrophic lateral sclerosis & frontotemporal degeneration.
18(5-6):351-357
[DOI] 10.1080/21678421.2017.1313868.
[PMID] 28425762.
2015
Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.
Annals of clinical and translational neurology.
2(5):465-78
[DOI] 10.1002/acn3.186.
[PMID] 26000320.
2014
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Current medical research and opinion.
30(11):2255-65
[DOI] 10.1185/03007995.2014.940040.
[PMID] 25062507.
2011
Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms.
Pain.
152(9):2036-2051
[DOI] 10.1016/j.pain.2011.04.033.
[PMID] 21641113.
2009
Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
The Clinical journal of pain.
25(5):376-85
[DOI] 10.1097/AJP.0b013e318196d2b6.
[PMID] 19454870.
2006
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Clinical therapeutics.
28(10):1607-18
[PMID] 17157116.
2006
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Annals of neurology.
59(5):780-7
[PMID] 16634036.
Grants
Sep 2024
ACTIVE
Surveillance of Muscular Dystrophies
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Dec 2023
– Nov 2024
ALS/MND NATURAL HISTORY REPOSITORY SITE AGREEMENT
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
Sep 2023
ACTIVE
Multimodal longitudinal imaging of brain and cervical cord as ALS disease biomarker using microstructure statistics and morphometry
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via US FOOD AND DRUG ADMN
Sep 2023
ACTIVE
Clinic-based Multicenter ALS Natural History Data Collection- Supplement
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via US FOOD AND DRUG ADMN
Sep 2023
ACTIVE
Safety of Metformin in C9orf72 ALS: Effects on RAN Proteins, Breathing, Imaging, and Metabolomic Outcome Measures
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
May 2023
ACTIVE
Regimen-Specific Appendix (RSA) F to Master Protocol ABBV-CLS-7262
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
via DENALI THERAPEUTICS
Apr 2023
ACTIVE
A Phase 2, randomised, double-blind, placebo-controlled, 2-way
crossover study to evaluate the efficacy, safety, and tolerability of
NMD670 in ambulatory adults with Type 3 spinal muscular
atrophy
Role: Principal Investigator
Funding: NMD PHARMA
Feb 2023
ACTIVE
Regimen-Specific Appendix (RSA) F to Master Protocol ABBV-CLS-7262
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
via CALICO LIFE SCIENCES
Dec 2022
– Nov 2024
Safety & therapeutic potential of metformin for C9orf72 ALS
Role: Co-Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Nov 2022
ACTIVE
CTOA Wymer
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Sep 2022
ACTIVE
Clinic-based Multicenter ALS Natural History Data Collection
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
via US FOOD AND DRUG ADMN
Aug 2022
– Nov 2024
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: MITSUBISHI TANABE PHARMA AMERICA
Aug 2022
– Jul 2024
PLS Natural History Project 2
Role: Principal Investigator
Funding: COLUMBIA UNIVERSITY MEDICAL CENTER
via AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2022
ACTIVE
Identifying and targeting novel repeat associated non-AUG (RAN) proteins in sporadic ALS
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Jul 2022
ACTIVE
Novel repeat associated non-AUG (RAN) proteins in sALS, sFTD and SBMA: shared pathological features and unifying therapeutic opportunities
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jun 2022
– Feb 2024
An Intermediate size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: BIONICAL LTD
via AMYLYX PHARMACEUTICALS
Jan 2022
– Jul 2024
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: PEACHTREE BIORESEARCH SOLUTIONS
via AMYLYX PHARMACEUTICALS
Jan 2022
ACTIVE
Acute adenosine receptor antagonism to promote breathing plasticity in ALS
Role: Co-Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2021
ACTIVE
CTOA – Multiple Sclerosis
Role: Principal Investigator
Funding: UNIV OF FLORIDA
May 2021
– Aug 2024
Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic study of Intravenous ANX005 in Subjects with Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: WORLDWIDE CLINICAL TRIALS
via ANNEXON
Apr 2021
– Dec 2024
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in
Charcot-Marie-Tooth Type 1A (CMT1A)
Role: Principal Investigator
Funding: PHARNEXT
Mar 2021
– Dec 2023
A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITSUBISHI TANABE PHARMA AMERICA
Dec 2020
– Nov 2023
A Phase 3, Multi-Center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITSUBISHI TANABE PHARMA AMERICA
Nov 2020
– Dec 2023
A pharmacokinetic and pharmacodynamic study of AMX0035 in patients with ALS
Role: Principal Investigator
Funding: AMYLYX PHARMACEUTICALS
Oct 2020
– Mar 2023
A Compassionate Use Protocol of AMX0035 for treatment of patients with Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: UNITED BIOSOURCE
via AMYLYX PHARMACEUTICALS
Jul 2020
– Jul 2022
PLS Natural History Study (PNHS)
Role: Principal Investigator
Funding: COLUMBIA UNIVERSITY
via SPASTIC PARAPLEGIA FOUNDATION
Feb 2020
– Nov 2022
A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITSUBISHI TANABE PHARMA AMERICA
Jan 2020
– Jan 2025
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients with ALS: Open-Label Extension for Patients Completing Study 3119002
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via ORION CORP
Jan 2020
ACTIVE
HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) A to Master Protocol, ZILUCOPLAN | Home Spirometry and Open-Label Extension (OLE) Period (add'l support for TO2)
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
via RA PHARMACEUTICALS
Jan 2020
ACTIVE
Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (A
LS): A perpetual multi-center, multi-regimen, clinical trial evaluating
the safety and efficacy of investigational products for the treatment
of ALS
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
Jan 2020
– Dec 2021
Quality of Life Grant MS Foundation
Role: Principal Investigator
Funding: MULTIPLE SCLEROSIS FOUNDATION
Jan 2020
– Jun 2020
Natural History Pilot Project- University of Florida
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Sep 2019
ACTIVE
Surveillance of muscular dystrophy in the Southeastern United States
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Nov 2018
ACTIVE
CTOA – General
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Aug 2018
– Aug 2023
EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via ORION CORP
Apr 2018
– Feb 2023
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis (ALS), Open Label Extension
Role: Principal Investigator
Funding: AMYLYX PHARMACEUTICALS
Jan 2018
– Jan 2023
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK 2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via CYTOKINETICS INC
Jan 2018
– Jan 2023
A Single Center Study to Evaluate the Effect of Riluzole Oral Soluble Film on Swallowing Safety in Individuals With Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: INVENTIV HEALTH CLINICAL LLC
via AQUESTIVE THERAPEUTICS
Dec 2017
– Dec 2022
A multicenter, 18-week open label safety and efficacy trial of Dalfampridine in primary lateral sclerosis
Role: Principal Investigator
Funding: HOSPITAL FOR SPECIAL SURGERY
via NORTHEAST ALS ASSO
Nov 2017
– Nov 2018
A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects with Charcot-Marie-Tooth Disease
Role: Principal Investigator
Funding: FLEX PHARMA INC
Oct 2017
– Oct 2022
A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar? Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: *MALLINCKRODT PHARMACEUTICALS-Bankrupt
Jul 2017
– Aug 2023
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) for a Treatment of Amyotropic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
via AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2017
– May 2022
A Program to develop a research database for the study of abnormal cellular components in Myasthenia Gravis: Specimen banking and data registry
Role: Principal Investigator
Funding: UF FOUNDATION
Apr 2017
– Mar 2023
Delineating Physiologic Mechanisms of Swallowing impairment and Decline in ALS
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2016
– Jul 2021
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects with Painful Diabetic Peripheral Neuropathy
Role: Principal Investigator
Funding: VIROMED CO LTD
Apr 2014
– Sep 2018
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
Role: Principal Investigator
Funding: UNIV OF KANSAS MEDICAL CTR
via PATIENT-CENTERED OUTCOMES RES INST
Education
Medical Degree
1984-1991
·
University of Maryland
Contact Details
Phones:
- Business:
- (352) 273-5550
Emails:
- Business:
- james.wymer@neurology.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100268
GAINESVILLE FL 32610 - Business Street:
-
3011 SW WILLISTON RD RM 1103
GAINESVILLE FL 32608